Abstract
Get full access to this article
View all access options for this article.
References
1.Food and Drug Administration, US Department of Health and Human Service . FDA approval in 1996 set new records . FDA Talk Paper January 14, 1997 .
2.
Carpenter
CCJ
Fischl
MA
Hammer
SA
Hirsch
MS
Jacobsen
DM
Katzenstein
DA
Antiretroviral therapy for HIV infection in 1997 . JAMA
1997 ;277 :1962 –9 .
3.
D'Agati
V
Appel
GB
. HIV infection and the kidney . J Am Soc Nephrol
1997 ;8 :138 –52 .
4.
Kopp
JB
Miller
KD
Mican
JAM
Feuerstein
IM
Vaughan
E
Baker
C
Crystalluria and urinary tract abnormalities associated with indinavir . Ann Intern Med
1997 ;127 :119 –25 .
5.Package insert . Crixivan (indinavir sulfate) . West Point, PA : Merck & Co. , 1996 .
6.
Daudon
M
Estèpa
L
Viard
JP
Joly
D
Jungers
P
. Urinary stones in HIV-1-positive patients treated with indinavir . Lancet
1997 ;349 :1294 –5 .
7.
Berns
JS
Cohen
RF
Silverman
M
Turner
J
. Acute renal failure to indinavir crystalluria and nephrolithiasis: Report of two cases . Am J Kidney Dis
1997 ;30 :558 –60 .
8.
Bruce
RG
Munch
LC
Hoven
AD
Jerauld
RS
Greenburg
R
Porter
WH
Urolithiasis associated with the protease inhibitor indinavir . Urology
1997 ;50 :513 –8 .
9.
Tashima
KT
Horowits
JD
Rosen
S
. Indinavir nephropathy (letter) . N Engl J Med
1997 ;336 :138 –40 .
10.
Bräu
N
Leaf
HL
Wieczorek
L
Margolis
DM
. Severe hepatitis in three AIDS patients treated with indinavir . Lancet
1997 ;29 :924 –5 .